Dr. Patrick Gariety shares his experiences as a treatment clinician working in a facility with about 300 psychiatric patients, staffed with five psychiatrists and eight psychologists. The psychiatric population was extremely mixed, with most of the patients suffering from some form of chronic mental illness, and/or severe personality disorders.

Since 2011, 3 new antidepressants have been approved by the FDA, and another (ketamine) has been generating buzz as a potential off-label medication for depression. In this article, we’ll take a step back and review the data on vilazodone (Viibryd), levomilnacipran (Fetzima), vortioxetine (Brintellix), and ketamine.

Dr. Bodkin discusses methods for approaching treatment resistant depression and his perspective on depressive illness as a final common pathway for a number of different brain problems.

Rates of autism diagnoses are on the rise. While no one knows for sure why, a new study explores whether the increased use of antidepressants during pregnancy might be one of the causes.

In October of 2004, the FDA announced to drug companies that they should add black-box warnings about the risk of suicidal behavior in children and adolescents started on antidepressants. How have these black-box warnings affected clinical practice over the past decade?

This Expert Q&A covers key things that John Walkup, MD, looks for in child and adolescent patients with depression to determine how they are likely to respond to different kinds of medication.

On July 10, the U.S. Food and Drug Administration (FDA) approved Otsuka and Lundbeck’s Rexulti (brexpiprazole) for schizophrenia and as an add-on to antidepressants for adults with depression. As the name suggests, it’s chemically and structurally related to aripiprazole (Abilify).

Learn about Trauma Systems Therapy (TST) and its use with young patients in an interview with Glenn Saxe, MD, Arnold Simon professor and chair, Department of Child and Adolescent Psychiatry, and director, the Child Study Center.

The psychiatric community continues to debate the value of the US Food and Drug Administration's (FDA) so-called ‘black box’ warning on certain antidepressants, and a pair of opposing viewpoints was recently featured in the New England Journal of Medicine.

Brief depression screening questionnaires are popular, especially with primary care providers (PCPs). However, a new study suggests that PCPs who use these questionnaires might be prescribing antidepressants to patients who don’t need them.